Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Active not recruiting 4Recruiting 2Withdrawn 1Terminated 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

zilucoplan 1toripalimab 1somapacitan 1rozanolixizumab 1pembrolizumab 1ibrutinib 1futibatinib 1exemestane 1enzalutamide 1durvalumab 1decitabine and cedazuridine drug combination 1cemiplimab 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Tamoxifen 1Robotic Surgical Procedures 1Observation 1Letrozole 1Lenalidomide 1JNJ-64619178 1JNJ-64264681 1Inosine Monophosphate 1Fulvestrant 1Folfox protocol 1Dexamethasone 1Cisplatin 1Carboplatin 1Bevacizumab 1Anastrozole 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × INDUSTRY × decitabine and cedazuridine drug combination × Clear all
NCT04093570 2025-10-31

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

Taiho Oncology, Inc.

Phase 2 Enrolling by invitation
332 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡